[{"Assets_0_Q3_USD":10942900000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":398700000.0,"NetIncomeLoss_1_Q3_USD":-67500000.0,"NetIncomeLoss_3_Q3_USD":49600000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":137400000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":139000000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":137400000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":138500000.0,"StockholdersEquity_0_Q3_USD":5659800000.0,"EarningsPerShareBasic_1_Q3_USD":-0.49,"EarningsPerShareBasic_3_Q3_USD":0.36,"EarningsPerShareDiluted_1_Q3_USD":-0.49,"EarningsPerShareDiluted_3_Q3_USD":0.36,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":1133100000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":3536500000.0,"Ticker":"PRGO","CIK":"1585364","name":"PERRIGO CO PLC","OfficialName":"Perrigo Company plc Ordinary Shares","form":"10-Q","period":"20180930","fy":"2018.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"4754722726.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20181108"}]